ArticleEClinicalMedicine2022

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

Linong Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.